Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the second quarter and six months ended June 30, 2013, and provided an operating forecast and program updates.
“We have had a very strong first half in 2013, and the coming quarters look promising as we anticipate further growth in royalty revenue, potential approvals for a new royalty-bearing drug and label expansions, NDA filings for partnered products and completing our first full year of operational profitability,” commented John Higgins, President and Chief Executive Officer of Ligand.
Help employers find you! Check out all the jobs and post your resume.
